CADL Candel Therapeutics Inc

Price (delayed)

$6.1

Market cap

$181.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.28

Enterprise value

$176.55M

Highlights
Candel Therapeutics's debt has decreased by 7% YoY and by 7% QoQ
Candel Therapeutics's EPS has decreased by 41% YoY but it has increased by 2.3% QoQ
Candel Therapeutics's equity has shrunk by 85% YoY and by 53% QoQ
CADL's quick ratio has dropped by 83% year-on-year and by 24% since the previous quarter

Key stats

What are the main financial stats of CADL
Market
Shares outstanding
29.74M
Market cap
$181.44M
Enterprise value
$176.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
29.94
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$34.73M
EBITDA
-$33.5M
Free cash flow
-$32.17M
Per share
EPS
-$1.28
Free cash flow per share
-$1.1
Book value per share
$0.2
Revenue per share
$0
TBVPS
$1.07
Balance sheet
Total assets
$31.22M
Total liabilities
$25.24M
Debt
$21.09M
Equity
$5.98M
Working capital
$13.6M
Liquidity
Debt to equity
3.53
Current ratio
2
Quick ratio
1.92
Net debt/EBITDA
0.15
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-82.5%
Return on equity
-206.1%
Return on invested capital
-206.4%
Return on capital employed
-196.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CADL stock price

How has the Candel Therapeutics stock price performed over time
Intraday
3.21%
1 week
4.81%
1 month
-19.53%
1 year
425.86%
YTD
314.97%
QTD
-1.61%

Financial performance

How have Candel Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$36.66M
Net income
-$37.37M
Gross margin
N/A
Net margin
N/A
The net income has declined by 40% year-on-year
The company's operating income rose by 4.5% QoQ but it fell by 3.4% YoY

Growth

What is Candel Therapeutics's growth rate over time

Valuation

What is Candel Therapeutics stock price valuation
P/E
N/A
P/B
29.94
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Candel Therapeutics's EPS has decreased by 41% YoY but it has increased by 2.3% QoQ
Candel Therapeutics's equity has shrunk by 85% YoY and by 53% QoQ

Efficiency

How efficient is Candel Therapeutics business performance
CADL's ROA has plunged by 149% YoY and by 18% from the previous quarter
The company's return on invested capital has shrunk by 105% YoY and by 16% QoQ
Candel Therapeutics's ROE has decreased by 44% from the previous quarter

Dividends

What is CADL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CADL.

Financial health

How did Candel Therapeutics financials performed over time
The total assets is 24% greater than the total liabilities
The current ratio has plunged by 83% YoY and by 23% from the previous quarter
CADL's quick ratio has dropped by 83% year-on-year and by 24% since the previous quarter
CADL's debt to equity has surged by 97% since the previous quarter
Candel Therapeutics's equity has shrunk by 85% YoY and by 53% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.